BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 10375557)

  • 1. CTLA-4 and T cell activation.
    Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
    Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.
    Linsley PS; Ledbetter J; Peach R; Bajorath J
    Res Immunol; 1995; 146(3):130-40. PubMed ID: 8525042
    [No Abstract]   [Full Text] [Related]  

  • 3. The complexities of T-cell co-stimulation: CD28 and beyond.
    Sperling AI; Bluestone JA
    Immunol Rev; 1996 Oct; 153():155-82. PubMed ID: 9010723
    [No Abstract]   [Full Text] [Related]  

  • 4. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
    van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
    Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
    [No Abstract]   [Full Text] [Related]  

  • 5. CD28 function: a balance of costimulatory and regulatory signals.
    Bour-Jordan H; Blueston JA
    J Clin Immunol; 2002 Jan; 22(1):1-7. PubMed ID: 11958588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system.
    Anderson DE; Sharpe AH; Hafler DA
    Curr Opin Immunol; 1999 Dec; 11(6):677-83. PubMed ID: 10631554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.
    Steiner K; Waase I; Rau T; Dietrich M; Fleischer B; Bröker BM
    Clin Exp Immunol; 1999 Mar; 115(3):451-7. PubMed ID: 10193417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of autoimmunity by inhibition of T cell costimulation.
    Daikh DI; Wofsy D
    Adv Exp Med Biol; 2001; 490():113-7. PubMed ID: 11505969
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses.
    Hathcock KS; Hodes RJ
    Adv Immunol; 1996; 62():131-66. PubMed ID: 8781268
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
    Lane P
    Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4-H gamma 1 transgenic mice.
    Lane P
    Res Immunol; 1995; 146(3):176-9. PubMed ID: 8525050
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of CTLA-4 in the regulation and initiation of T-cell responses.
    Chambers CA; Krummel MF; Boitel B; Hurwitz A; Sullivan TJ; Fournier S; Cassell D; Brunner M; Allison JP
    Immunol Rev; 1996 Oct; 153():27-46. PubMed ID: 9010718
    [No Abstract]   [Full Text] [Related]  

  • 13. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
    Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
    Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New protein steals the show as 'costimulator' of T cells.
    Cohen J
    Science; 1993 Nov; 262(5135):844-5. PubMed ID: 7694360
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of B7 costimulation in T-cell immunity.
    Harris NL; Ronchese F
    Immunol Cell Biol; 1999 Aug; 77(4):304-11. PubMed ID: 10457196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New molecules on dendritic cells and their interactions with T lymphocytes.
    Hart DN; Starling GC; Egner W; Hock BD; McLellan AD; McKenzie JL; Williams LA; Simmons DL
    Adv Exp Med Biol; 1995; 378():351-4. PubMed ID: 8526091
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.
    Boussiotis VA; Freeman GJ; Gribben JG; Nadler LM
    Immunol Rev; 1996 Oct; 153():5-26. PubMed ID: 9010717
    [No Abstract]   [Full Text] [Related]  

  • 18. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
    J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
    Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
    Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
    Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
    Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.